Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Mar. 31, 2020 | May 07, 2020 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2020 | |
Current Fiscal Year End Date | --06-30 | |
Entity File Number | 000-56035 | |
Entity Registrant Name | Global Wholehealth Partners Corp | |
Entity Central Index Key | 0001598308 | |
Entity Tax Identification Number | 46-2316220 | |
Entity Incorporation, State or Country Code | NV | |
Entity Address, Address Line One | 2227 Avenida Oliva | |
Entity Address, Address Line Two | San Clemente, California | |
Entity Address, City or Town | California | |
Entity Address, State or Province | NV | |
Entity Address, Postal Zip Code | 92673 | |
City Area Code | (714) | |
Local Phone Number | 392-9752 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 58,116,358 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Mar. 31, 2020 | Jun. 30, 2019 |
Current assets: | ||
Cash | $ 668 | $ 19,918 |
Inventory | 23,372 | |
Total current assets | 24,040 | 19,918 |
Total assets | 24,040 | 19,918 |
Current liabilities: | ||
Related party note | 62,875 | |
Related party advances | 1,500 | |
Accounts payable and accrued liabilities | 1,372 | 100 |
Total current liabilities | 65,747 | 100 |
Total liabilities | 65,747 | 100 |
Stockholders' equity (deficit): | ||
Preferred stock; $0.001 par value, 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2020 and June 30, 2019, respectively | ||
Common stock; $0.001 par value, 400,000,000 shares authorized, 58,116,358 and 56,116,358 shares issued and outstanding at March 31, 2020 and June 30, 2019, respectively | 58,116 | 56,116 |
Additional paid-in capital | 444,784 | 426,784 |
Retained deficit | (544,607) | (463,082) |
Total stockholders' equity | (41,707) | 19,818 |
Total liabilities and stockholders' equity | $ 24,040 | $ 19,918 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2020 | Jun. 30, 2019 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value per share | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value per share | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 400,000,000 | 400,000,000 |
Common stock, shares issued | 58,116,358 | 56,116,358 |
Common stock, shares outstanding | 58,116,358 | 56,116,358 |
Consolidated Statements Of Oper
Consolidated Statements Of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | |
Income Statement [Abstract] | ||||
Revenue | ||||
Operating expense | ||||
Professional fees | 9,000 | 6,738 | 44,900 | 6,738 |
Research and development | 443,750 | 443,750 | ||
Selling, general and administrative | 2,629 | 2,270 | 36,625 | 2,870 |
Total operating expense | 455,379 | 9,008 | 525,275 | 9,608 |
Loss from operations | (455,379) | (9,008) | (525,275) | (9,608) |
Other income | ||||
Gain on forgiveness of liabilities | 443,750 | 443,750 | ||
Net loss | $ (11,629) | $ (9,008) | $ (81,525) | $ (9,608) |
Basic and Diluted Loss per Common Share | $ 0 | $ (0.17) | $ 0 | $ (0.18) |
Weighted average number of common shares outstanding - basic and diluted | 58,116,358 | 52,358 | 57,343,755 | 52,358 |
Consolidated Statements Of Stoc
Consolidated Statements Of Stockholders Deficit (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Deficit [Member] | Total |
Balance, common shares at Jun. 30, 2018 | 52,358 | |||
Balance, amount at Jun. 30, 2018 | $ 52 | $ 430,748 | $ (432,215) | $ (1,415) |
Net loss | (300) | (300) | ||
Balance, common shares at Sep. 30, 2018 | 52,358 | |||
Balance, amount at Sep. 30, 2018 | $ 52 | 430,748 | (432,515) | (1,715) |
Balance, common shares at Jun. 30, 2018 | 52,358 | |||
Balance, amount at Jun. 30, 2018 | $ 52 | 430,748 | (432,215) | (1,415) |
Net loss | (9,608) | |||
Balance, common shares at Mar. 31, 2019 | 52,358 | |||
Balance, amount at Mar. 31, 2019 | $ 52 | 430,748 | (441,823) | (11,023) |
Balance, common shares at Sep. 30, 2018 | 52,358 | |||
Balance, amount at Sep. 30, 2018 | $ 52 | 430,748 | (432,515) | (1,715) |
Net loss | (300) | (300) | ||
Balance, common shares at Dec. 31, 2018 | 52,358 | |||
Balance, amount at Dec. 31, 2018 | $ 52 | 430,748 | (432,815) | (2,015) |
Net loss | (9,008) | (9,008) | ||
Balance, common shares at Mar. 31, 2019 | 52,358 | |||
Balance, amount at Mar. 31, 2019 | $ 52 | 430,748 | (441,823) | $ (11,023) |
Balance, common shares at Jun. 30, 2019 | 56,116,358 | 56,116,358 | ||
Balance, amount at Jun. 30, 2019 | $ 56,116 | 426,784 | (463,082) | $ 19,818 |
Net loss | (18,798) | (18,798) | ||
Balance, common shares at Sep. 30, 2019 | 56,116,358 | |||
Balance, amount at Sep. 30, 2019 | $ 56,116 | 426,784 | (481,880) | $ 1,020 |
Balance, common shares at Jun. 30, 2019 | 56,116,358 | 56,116,358 | ||
Balance, amount at Jun. 30, 2019 | $ 56,116 | 426,784 | (463,082) | $ 19,818 |
Net loss | $ (81,525) | |||
Balance, common shares at Mar. 31, 2020 | 58,116,358 | 58,116,358 | ||
Balance, amount at Mar. 31, 2020 | $ 58,116 | 444,784 | (544,607) | $ (41,707) |
Balance, common shares at Sep. 30, 2019 | 56,116,358 | |||
Balance, amount at Sep. 30, 2019 | $ 56,116 | 426,784 | (481,880) | 1,020 |
Common stock issued to related party for cash at $0.01 per share, shares | 2,000,000 | |||
Common stock issued to related party for cash at $0.01 per share, amount | $ 2,000 | 18,000 | 20,000 | |
Net loss | (51,098) | (51,098) | ||
Balance, common shares at Dec. 31, 2019 | 58,116,358 | |||
Balance, amount at Dec. 31, 2019 | $ 58,116 | 444,784 | (532,978) | (30,078) |
Net loss | (11,629) | $ (11,629) | ||
Balance, common shares at Mar. 31, 2020 | 58,116,358 | 58,116,358 | ||
Balance, amount at Mar. 31, 2020 | $ 58,116 | $ 444,784 | $ (544,607) | $ (41,707) |
Consolidated Statements Of St_2
Consolidated Statements Of Stockholders Deficit (Unaudited) (Parenthetical) | Mar. 31, 2020$ / shares |
Statement of Stockholders' Equity [Abstract] | |
Stock issued to related party price per share | $ 0.01 |
Consolidated Statements Of Cash
Consolidated Statements Of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Cash flows from operating activities | ||
Net loss | $ (81,525) | $ (9,608) |
Adjustments to reconcile net loss to net cash flows used in operating activities: | ||
Common stock issued for services | ||
Common stock issued for debt settlement | ||
Changes in operating assets and liabilities: | ||
(Increase) decrease in inventory | 23,372 | |
Increase (decrease) in related party advances | 1,500 | 10,923 |
Increase (decrease) in accounts payable and accrued expenses | 1,272 | (1,315) |
Net cash flows from operating activities | (102,125) | |
Cash flows from financing activities | ||
Cash for common shares of stock | 20,000 | |
Proceeds from related party note, net | 62,875 | |
Net cash flows from financing activities | 82,875 | |
Change in cash | (19,250) | |
Cash at beginning of period | 19,918 | |
Cash at end of period | 668 | |
Supplemental disclosure of cash flow information: | ||
Interest paid in cash | ||
Income taxes paid in cash |
Basis Of Presentation, Organiza
Basis Of Presentation, Organization And Going Concern | 9 Months Ended |
Mar. 31, 2020 | |
Basis Of Presentation Organization And Going Concern | |
Basis of Presentation, Organization and Going Concern | NOTE 1 – Basis of Presentation, Organization and Going Concern Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of Global WholeHealth Partners Corporation and Subsidiary (the “Company”) as of March 31, 2020, and for the three and nine months ended March 31, 2020 and 2019, include the accounts of the Company and its wholly-owned and controlled subsidiary, Global WholeHealth Partners Corp, a private Wyoming corporation, and have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”), for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10 for the year ended June 30, 2019.In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s financial position as of December 31, 2019, results of operations for the three and nine months ended March 31, 2020 and 2019, and stockholders’ equity and cash flows for the three and nine months ended March 31, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. Organization Global WholeHealth Partners Corporation was incorporated on March 7, 2013 in the State of Nevada under the name Texas Jack Oil and Gas Corp. On May 9, 2019, the Company amended its Articles of Incorporation to effect a change of name to Global WholeHealth Partners Corporation to align the company name with its focus on health care related development and products. The Company’s ticker symbol changed to GWHP. The Company was originally organized for the purpose of exploration of Oil and Gas. However, the Company was unable to establish an oil and gas concern and was abandoned in 2016. On February 27, 2019, the Clark County District Court of Nevada appointed Barbara Bauman as custodian to the Company. The custodian reestablished the Company in good standing. On May 9, 2019, the Board reverse split (1-for-500) the outstanding Common Shares of 58,172,000 to 116,358 shares. May 23, 2019, the Company and LionsGate Funding Group LLC (“LionsGate”), owner of a majority of the Company’s outstanding common stock as of May 23, 2019, entered into a Stock Sale and Purchase Agreement (the “SPA”) which closed on June 27, 2019. Pursuant the SPA, the Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp., a private Wyoming corporation incorporated on April 9, 2019 (“Global Private”). Global Private has contacts with suppliers and contract manufacturers in the In vitro diagnostic industry, with rights to sell rapid diagnostic tests, such as the following 6 minute rapid whole blood Ebola Test, 6 minute whole blood Zika test, 8 minute whole blood rapid TB test and 75 plus other tests more than 40 which are FDA approved. Due to the common control of the Company and Global Private, pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control”, the SPA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. Financial statement presentation under the predecessor values method of accounting as a result of a business combination between entities under common control requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements include both entities’ full results since the inception of Global Private. Going Concern The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $544,607. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds, and funds from the sale of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements. |
Summary Of Significant Accounti
Summary Of Significant Accounting Policies | 9 Months Ended |
Mar. 31, 2020 | |
Summary Of Significant Accounting Policies | |
Summary of Significant Accounting Policies | NOTE 2 – Summary of Significant Accounting Policies Principles of Consolidation Global WholeHealth Partners Corp, a private Wyoming corporation was incorporated on April 9, 2019 to receive private investor funds and aggregate certain in vitro diagnostic assets. These consolidated financial statements presented are those of Global WholeHealth Partners Corporation and its wholly owned subsidiary, Global Private. All significant intercompany balances and transactions have been eliminated. Accounting estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. Cash and cash equivalents The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents. Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. During the periods covered by this report, the Company did not have any assets or liabilities that were required to be measured at fair value on a recurring basis or on a non-recurring basis. Fair Value of Financial Instruments The Company’s financial instruments consist of cash, accounts payable and accrued expenses. The carrying amounts of the Company’s financial instruments approximate fair value because of the short term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect those estimates. We do not hold or issue financial instruments for trading purposes, nor do we utilize derivative instruments. Net Income (Loss) Per Share The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The Company had no potentially dilutive securities as of December 31, 2019. New Accounting Pronouncements Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to us, we have not identified any standards that we believe merit discussion. We believe that none of the new standards will have a significant impact on our consolidated financial statements. |
Stockholder's Equity
Stockholder's Equity | 9 Months Ended |
Mar. 31, 2020 | |
Stockholders Equity | |
Stockholder’s Equity | NOTE 3 – Stockholder’s Equity Preferred Stock The Company has Preferred stock: $0.001 par value; 10,000,000 shares authorized with no shares issued and outstanding. Common Stock The Company has 400,000,000 shares of Common Stock authorized of which 58,116,358 and 56,116,358 shares were issued and outstanding as of March 31, 2020 and June 30, 2019, respectively. During the nine months ended March 31, 2020, the number of shares increased by 2,000,000 as a result of the Company selling 2,000,000 shares at $0.01 per share to LionsGate in exchange for cash of $20,000. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Mar. 31, 2020 | |
Related Party Transactions | |
Related Party Transactions | NOTE 4 – Related Party Transactions During the nine months ended March 31, 2020, the Company received $20,000 upon the sale of 2,000,000 shares of common stock to LionsGate for $0.01 per share. From time-to-time the Company receives shareholder advances to cover operating costs which are reflected on the balance sheet as related party advances. During the three months ended March 31, 2020, LionsGate provided advances totaling $455,950 which was used to pay professional fees of $11,100, research studies for the development of its CoVid-19 tests of $443,750 and general costs of $1,100. During the nine months ended March 31, 2020, LionsGate provided advances totaling $506,625 which was used to pay professional fees of $46,000, research studies for the development of CoVid-19 tests of $443,750 and general costs of $16,875. During the three months ended March 31, 2020, the Company paid $431,250 to Pan Probe Biotech to perform studies in validation of the Company’s CoVid-19 tests. Dr. Shujie Cui is the Company’s Chief Science Officer and 100% owner of Pan Probe. |
Promissory Note
Promissory Note | 9 Months Ended |
Mar. 31, 2020 | |
Promissory Note | |
Promissory Note | NOTE 5 – Promissory Note On March 29, 2020, the Company issued a Promissory Note (the “ Note The Note was issued by the Company under the exemption from registration afforded by Section 4(a)(2) of the Securities Act, as amended and/or Regulation D promulgated thereunder, as the securities were issued to accredited investors, without a view to distribution, and were not issued through any general solicitation or advertisement. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Mar. 31, 2020 | |
Subsequent Events | |
Subsequent Events | NOTE 6 – Subsequent Events Management has reviewed material events subsequent of the period ended March 31, 2020 and prior to the filing of our consolidated financial statements in accordance with FASB ASC 855 “Subsequent Events”. The recent outbreak of the novel coronavirus CoVid-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company’s employees and R&D activities. The CoVid-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s vendors as a result of quarantines, facility closures, and travel and logistics restrictions. The extent to which the CoVid-19 pandemic impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the CoVid-19 pandemic, the effects of the CoVid-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local, state and federal governments, and to what extent normal economic and operating conditions can resume. Even after the CoVid-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time. |
Basis of Presentation, Organi_2
Basis of Presentation, Organization And Going Concern (Policies) | 9 Months Ended |
Mar. 31, 2020 | |
Disclosure Basis Of Presentation Organization And Going Concern Policies Abstract | |
Basis of Presentation | Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of Global WholeHealth Partners Corporation and Subsidiary (the “Company”) as of March 31, 2020, and for the three and nine months ended March 31, 2020 and 2019, include the accounts of the Company and its wholly-owned and controlled subsidiary, Global WholeHealth Partners Corp, a private Wyoming corporation, and have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”), for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10 for the year ended June 30, 2019.In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s financial position as of December 31, 2019, results of operations for the three and nine months ended March 31, 2020 and 2019, and stockholders’ equity and cash flows for the three and nine months ended March 31, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. |
Organization | Organization Global WholeHealth Partners Corporation was incorporated on March 7, 2013 in the State of Nevada under the name Texas Jack Oil and Gas Corp. On May 9, 2019, the Company amended its Articles of Incorporation to effect a change of name to Global WholeHealth Partners Corporation to align the company name with its focus on health care related development and products. The Company’s ticker symbol changed to GWHP. The Company was originally organized for the purpose of exploration of Oil and Gas. However, the Company was unable to establish an oil and gas concern and was abandoned in 2016. On February 27, 2019, the Clark County District Court of Nevada appointed Barbara Bauman as custodian to the Company. The custodian reestablished the Company in good standing. On May 9, 2019, the Board reverse split (1-for-500) the outstanding Common Shares of 58,172,000 to 116,358 shares. May 23, 2019, the Company and LionsGate Funding Group LLC (“LionsGate”), owner of a majority of the Company’s outstanding common stock as of May 23, 2019, entered into a Stock Sale and Purchase Agreement (the “SPA”) which closed on June 27, 2019. Pursuant the SPA, the Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp., a private Wyoming corporation incorporated on April 9, 2019 (“Global Private”). Global Private has contacts with suppliers and contract manufacturers in the In vitro diagnostic industry, with rights to sell rapid diagnostic tests, such as the following 6 minute rapid whole blood Ebola Test, 6 minute whole blood Zika test, 8 minute whole blood rapid TB test and 75 plus other tests more than 40 which are FDA approved. Due to the common control of the Company and Global Private, pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control”, the SPA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. Financial statement presentation under the predecessor values method of accounting as a result of a business combination between entities under common control requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements include both entities’ full results since the inception of Global Private. |
Going Concern | Going Concern The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $544,607. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds, and funds from the sale of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements. |
Summary Of Significant Accoun_2
Summary Of Significant Accounting Policies (Policies) | 9 Months Ended |
Mar. 31, 2020 | |
Disclosure Summary Of Significant Accounting Policies Policies Abstract | |
Principles of Consolidation | Principles of Consolidation Global WholeHealth Partners Corp, a private Wyoming corporation was incorporated on April 9, 2019 to receive private investor funds and aggregate certain in vitro diagnostic assets. These consolidated financial statements presented are those of Global WholeHealth Partners Corporation and its wholly owned subsidiary, Global Private. All significant intercompany balances and transactions have been eliminated. |
Accounting estimates | Accounting estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. |
Cash and cash equivalents | Cash and cash equivalents The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents. |
Income Taxes | Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively. |
Fair Value Measurements | Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. During the periods covered by this report, the Company did not have any assets or liabilities that were required to be measured at fair value on a recurring basis or on a non-recurring basis. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company’s financial instruments consist of cash, accounts payable and accrued expenses. The carrying amounts of the Company’s financial instruments approximate fair value because of the short term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect those estimates. We do not hold or issue financial instruments for trading purposes, nor do we utilize derivative instruments. |
Net Income (Loss) Per Share | Net Income (Loss) Per Share The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The Company had no potentially dilutive securities as of December 31, 2019. |
New Accounting Pronouncements | New Accounting Pronouncements Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to us, we have not identified any standards that we believe merit discussion. We believe that none of the new standards will have a significant impact on our consolidated financial statements. |
Organization (Narrative) (Detai
Organization (Narrative) (Details) - Common Stock [Member] - shares | May 23, 2019 | May 09, 2019 |
Reverse stock split | 1-for-500 | |
Reverse stock split outstanding common stock | 58,172,000 | |
Reverse stock split during the period | 116,358 | |
LionsGate Funding Group LLC [Member] | ||
Exchange of common stock shares to Lion gate | The Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp |
Related Party Transactions (Nar
Related Party Transactions (Narrative) (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | |
Related Party Transaction [Line Items] | |||||
Common stock issued to related party, amount | $ 20,000 | ||||
Stock issued to related party price per share | $ 0.01 | $ 0.01 | |||
Advances from related party | $ 62,875 | ||||
Professional fees | $ 9,000 | $ 6,738 | 44,900 | 6,738 | |
Research studies for development of Co Vid -19 tests | 443,750 | 443,750 | |||
Common Stock [Member] | |||||
Related Party Transaction [Line Items] | |||||
Common stock issued to related party, shares | 2,000,000 | ||||
Common stock issued to related party, amount | $ 2,000 | ||||
LionsGate Funding Group LLC [Member] | |||||
Related Party Transaction [Line Items] | |||||
Stock issued to related party price per share | $ 0.01 | $ 0.01 | |||
Advances from related party | 455,950 | 506,625 | |||
Professional fees | 11,100 | 46,000 | |||
Research studies for development of Co Vid -19 tests | 443,750 | 443,750 | |||
General costs | 1,100 | $ 16,875 | |||
LionsGate Funding Group LLC [Member] | Common Stock [Member] | |||||
Related Party Transaction [Line Items] | |||||
Common stock issued to related party, shares | 2,000,000 | ||||
Common stock issued to related party, amount | $ 20,000 | ||||
Dr. Shujie Cui Is The Company's Chief Science Officer And Owner Of Pan Probe Biotech [Member] | |||||
Related Party Transaction [Line Items] | |||||
Paid to Pan Probe Biotech to perform studies | $ 431,250 | ||||
Related Party Description | During the three months ended March 31, 2020, the Company paid $431,250 to Pan Probe Biotech to perform studies in validation of the Company’s COVID-19 tests. Dr. Shujie Cui is the Company’s Chief Science Officer and 100% owner of Pan Probe |
Promissory Note (Narrative) (De
Promissory Note (Narrative) (Details) - USD ($) | Mar. 30, 2020 | Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2020 | Mar. 31, 2019 | Mar. 29, 2020 |
Short-term Debt [Line Items] | |||||||
Research and development expenses | $ 443,750 | $ 443,750 | |||||
LionsGate Funding Group LLC [Member] | |||||||
Short-term Debt [Line Items] | |||||||
Research and development expenses | 443,750 | 443,750 | |||||
LionsGate Funding Group LLC [Member] | Promissory Note [Member] | |||||||
Short-term Debt [Line Items] | |||||||
Debt instrument face amount | $ 506,625 | ||||||
Research and development expenses | $ 443,750 | ||||||
Other Income | 443,750 | $ 443,750 | |||||
Debt instrument carrying amount | $ 62,875 | $ 62,875 | $ 62,875 | ||||
Proceeds from issuance of notes payable | 585,000 | ||||||
Additional issuance of notes payable | $ 78,375 | ||||||
Promissory note interest rate | 5.00% | ||||||
Promissory notes description | The Note bears interest at the rate of 5% per annum and the principal and interest is due and payable in full in 90 days on June 30, 2020. If not paid within the 90 days a 5% penalty will be added to the Note and the term will extend for an additional 90 days. | ||||||
Promissory notes maturity date | Jun. 30, 2020 |